Tirzepatide vs Semaglutide: Which Is Worth It in 2026?

Two medications have changed weight loss medicine. Semaglutide (the active ingredient in Ozempic and Wegovy) launched the GLP-1 era. Tirzepatide (Mounjaro, Zepbound) followed — and in clinical trials, outperformed semaglutide by a substantial margin.

The question most patients ask: which one should I take?

The answer depends on your goals, your physiology, your budget, and your tolerance for side effects. Here's an honest breakdown.

The Clinical Data

Let's start with what the trials actually show.

Semaglutide (STEP trials): At 2.4mg weekly, average weight loss was 14.9% of body weight at 68 weeks. About 35% of patients lost 20% or more. In people with diabetes, weight loss is somewhat lower (8-10% at standard doses).

Tirzepatide (SURMOUNT trials): At 15mg weekly (maximum dose), average weight loss was 20.9% at 72 weeks. About 57% of patients lost 20% or more. At 10mg, average was 19.5%.

This isn't close. Tirzepatide produces meaningfully better average outcomes — roughly 6 percentage points more weight loss at maximum doses. For a 250-pound person, that's 15 additional pounds on average. The gap in responders (people who lose 20%+) is even wider: 57% vs 35%.

Why does tirzepatide win? It's a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors amplify the appetite suppression and metabolic effects of GLP-1 activation. The combination appears more powerful than GLP-1 alone.

Side Effect Comparison

The side effect profiles are broadly similar, with some differences.

Semaglutide common side effects: Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Most side effects are GI-related and concentrated in the titration phase (weeks 1-12).

Tirzepatide common side effects: Nausea (31%), diarrhea (23%), vomiting (13%), constipation (17%). In the SURMOUNT trials, tirzepatide had *lower* rates of GI side effects despite producing more weight loss — a meaningful clinical advantage.

Why? The dual agonism may reduce the GI burden of any single receptor's activation. Pure speculation on mechanism, but the data is clear: tirzepatide tends to be better tolerated despite being more effective.

Rare but serious risks (both medications): Potential risk of medullary thyroid cancer (contraindicated if personal/family history); pancreatitis risk (rare, ~0.1%); gallbladder disease. These risks are theoretical or very rare in practice but real enough to take the contraindication screening seriously.

2026 Pricing Reality

Brand-name pricing is essentially irrelevant for most people — insurance coverage for branded GLP-1s remains extremely limited, and list prices are prohibitive.

Brand-name (without insurance): - Wegovy (semaglutide 2.4mg): ~$1,300-1,400/month - Zepbound (tirzepatide 15mg): ~$1,000-1,100/month (Eli Lilly's direct program)

Compounded (typical 2026 pricing): - Compounded semaglutide: $150-300/month depending on dose and provider - Compounded tirzepatide: $250-450/month depending on dose and provider

Tirzepatide costs more to compound because it's a more complex molecule and the peptide supply chains differ. The premium is roughly $100-150/month — meaningful but not prohibitive.

The math on cost-per-pound-lost: If tirzepatide helps you lose 6% more body weight and you weigh 220 pounds, that's 13 extra pounds. At $150/month premium over 18 months of treatment, you're paying roughly $2,700 extra to lose those 13 pounds — or about $207 per pound. Whether that's worth it depends entirely on your individual circumstances.

When to Choose Semaglutide

Semaglutide is the right choice when: - Budget is a real constraint (the ~$100-150/month savings matters) - You have a history of GI sensitivity and want the option to titrate more slowly with a more established protocol - You have diabetes — semaglutide's cardiovascular benefits in diabetes are extensively documented (SUSTAIN trials) - You've tolerated semaglutide before and have a good response - Your target weight loss is 10-15% of body weight (semaglutide fully achieves this for most responders)

When to Choose Tirzepatide

Tirzepatide is the right choice when: - You need maximum weight loss outcomes (BMI 40+, serious comorbidities, significant weight-related health issues) - You've tried semaglutide and had suboptimal response or poor tolerance - GI side effects are a major concern — tirzepatide's lower GI burden is a real advantage - You have insulin resistance or metabolic syndrome — tirzepatide's GIP activation improves insulin sensitivity significantly - The budget difference is manageable

What Happens If You Don't Respond?

About 15-20% of people are weak or non-responders to semaglutide. If you've been on adequate doses (1mg+) for 12+ weeks without meaningful weight loss, the semaglutide protocol isn't working. Switching to tirzepatide is a reasonable next step — the dual mechanism engages different receptor pathways and many non-responders to semaglutide respond to tirzepatide.

The reverse is also true but less well-documented: tirzepatide non-responders sometimes switch to semaglutide. Clinical data here is sparse.

The Practical Recommendation

If you're starting from zero, have a meaningful amount of weight to lose (30+ pounds), and can manage the cost: start with tirzepatide. The efficacy advantage is real and well-documented. The tolerability advantage is real. You'd be choosing the more effective medication from day one.

If budget is a constraint or you have specific reasons to prefer semaglutide (diabetes with established cardiovascular history, previous good response): semaglutide is an excellent medication with extensive long-term safety data and very good efficacy.

The worst choice is doing nothing because you can't decide. Both medications work. Both are dramatically better than any non-GLP-1 weight loss approach for most patients with significant weight to lose.

Marrow's Approach

Marrow offers both compounded semaglutide and tirzepatide. Your physician review includes a discussion of which protocol fits your profile, goals, and health history. There's no financial incentive to push one over the other — we want the protocol that produces results, because results are what keeps patients engaged long-term.

The intake takes 15 minutes. Your physician reviews your case before prescribing. Medication ships to your door. If you're not sure which to choose, that's a conversation for your physician consultation — not something you need to decide before starting.